RightFrontier Review
Medicare Drug Talks Risk Fewer New Cures, Industry Analysts Caution
As negotiation expands to 30 more medicines, skeptics say the program’s savings are borrowed against the pipeline of drugs that don’t yet exist.
Zara Desai · · 5 min read